Farnesyltransferase and geranylgeranyltransferase I: Structures, mechanism, inhibitors and molecular modeling

Drug Discovery Today

Volumn 20, Issue 2, 2015, Pages 267-276

  Shen, Mingyun ^a,b   Pan, Peichen ^a,b   Li, Youyong ^a   Li, Dan ^b   Yu, Huidong ^c   Hou, Tingjun ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Crystal Pharmatech   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ENZYME INHIBITOR; GERANYLGERANYLTRANSFERASE I; GGTI 2154; GGTI 2417; GGTI 2418; GGTI 287; GGTI DU 40; L 778123; LONAFARNIB; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; P 61 A 6; PROTEIN FARNESYLTRANSFERASE; TIPIFARNIB; TRANSFERASE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; FARNESYL TRANS TRANSFERASE; GERANYLGERANYLTRANSFERASE TYPE-I;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING SITE; BREAST TUMOR; CELL MEMBRANE; DRUG INDICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME MECHANISM; ENZYME STRUCTURE; GLAUCOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROGEN BOND; LEUKEMIA; METASTASIS; MOLECULAR MECHANICS; MOLECULAR MODEL; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NONHUMAN; PANCREAS TUMOR; PARASITOSIS; PROGERIA; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; FARNESYLTRANSTRANSFERASE; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84922953886     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.10.002     Document Type: Review

References (81)

1. A. Young Ras signaling and therapies G.F.V. Woude, G. Klein, Advances in Cancer Research Vol. 102 2009 Elsevier 1 17
2. J.L. Bos Ras oncogenes in human cancer - a review Cancer Res. 49 1989 4682 4689
3. M.S. Brose BRAF and RAS mutations in human lung cancer and melanoma Cancer Res. 62 2002 6997 7000
4. K. Walker, and M.F. Olson Targeting Ras and Rho GTPases as opportunities for cancer therapeutics Curr. Opin. Genet. Dev. 15 2005 62 68
5. I.M. Ahearn Regulating the regulator: post-translational modification of RAS Nat. Rev. Mol. Cell Biol. 13 2012 39 51
6. U.T.T. Nguyen Understanding and exploiting protein prenyltransferases Chembiochem 11 2010 1194 1201
7. S. Fletcher Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents J. Med. Chem. 53 2010 6867 6888
8. S.F. Sousa Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem Curr. Med. Chem. 15 2008 1478 1492
9. B.C. Capell Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome Proc. Natl. Acad. Sci. U. S. A. 102 2005 12879 12884
10. M.P. Glenn Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites Angew. Chem. Int. Ed. 44 2005 4903 4906
11. M.I. Esteva Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi J. Med. Chem. 48 2005 7186 7191
12. M. Ibrahim Identification and characterisation of Toxoplasma gondii protein farnesyltransferase Int. J. Parasitol. 31 2001 1489 1497
13. F.S. Buckner Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major Mol. Biochem. Parasitol. 122 2002 181 188
14. Y. Reiss Inhibition of purified p21ras farnesyl: protein transferase by Cys-AAX tetrapeptides Cell 62 1990 81
15. P. Dunten Protein farnesyltransferase: structure and implications for substrate binding Biochemistry 37 1998 7907 7912
16. M.C. Seabra Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit Cell 65 1991 429 434
17. B. Stephen Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate Biochemistry 37 1998 9612 9618
18. J. Gao CAAX-box protein, prenylation process and carcinogenesis Am. J. Transl. Res. 1 2009 312
19. H.W. Park Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution Science 275 1997 1800 1804
20. H-W. Fu Kinetic analysis of zinc ligand mutants of mammalian protein farnesyltransferase Biochemistry 37 1998 4465 4472
21. F.L. Zhang, and P.J. Casey Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I Biochem. J. 320 1996 925
22. S. McTaggart Isoprenylated proteins Cell. Mol. Life Sci. 63 2006 255 267
23. S.B. Long Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate Biochemistry 37 1998 9612 9618
24. H-W. Fu Identification of a cysteine residue essential for activity of protein farnesyltransferase J. Biol. Chem. 271 1996 28541 28548
25. A.D. Cox, and C.J. Der Ras family signaling-therapeutic targeting Cancer Biol. Ther. 1 2002 599 606
26. K. Kontani Di-Ras, a distinct subgroup of Ras family GTPases with unique biochemical properties J. Biol. Chem. 277 2002 41070 41078
27. C.D. Nobes A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion J. Cell Biol. 141 1998 187 197
28. B.T. Kinsella Carboxyl-terminal isoprenylation of Ras-related GTP-binding proteins encoded by Rac1, Rac2, and Rala J. Biol. Chem. 266 1991 9786 9794
29. D.B. Whyte K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J. Biol. Chem. 272 1997 14459 14464
30. F.L. Zhang Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I J. Biol. Chem. 272 1997 10232 10239
31. M. Liu Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer Proc. Natl. Acad. Sci. U. S. A. 107 2010 6471 6476
32. A.D. Basso Thematic review series: lipid posttranslational modifications. Farnesyl transferase inhibitors J. Lipid Res. 47 2006 15 31
33. J. Lu In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I Mol. Cancer Ther. 8 2009 1218 1226
34. M. Copland BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood 111 2008 2843 2853
35. A. Kazi Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy Mol. Cell. Biol. 29 2009 2254 2263
36. M. Alsina Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma Blood 103 2004 3271 3277
37. E.S. Kim Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma Cancer 104 2005 561 569
38. J.Z. Sun Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice Cancer Res. 63 2003 8922 8929
39. J.A. Sparano Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide J. Clin. Oncol. 24 2006 3013 3018
40. M. Eriksson Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome Nature 423 2003 293 298
41. R.D. Goldman Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome Proc. Natl. Acad. Sci. U. S. A. 101 2004 8963 8968
42. M.W. Glynn, and T.W. Glover Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition Hum. Mol. Genet. 14 2005 2959 2969
43. L.B. Gordon Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome Proc. Natl. Acad. Sci. U. S. A. 109 2012 16666 16671
44. D. Chakrabarti Protein farnesyltransferase and protein prenylation in Plasmodium falciparum J. Biol. Chem. 277 2002 42066 42073
45. L. Nallan Protein farnesyltransferase inhibitors exhibit potent antimalarial activity J. Med. Chem. 48 2005 3704 3713
46. J. Ohkanda Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity Bioorg. Med. Chem. Lett. 11 2001 761 764
47. K. Kohring Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials ChemMedChem 3 2008 1217 1231
48. J. Wiesner Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo Angew. Chem. Int. Ed. Engl. 43 2004 251 254
49. J.E. Lancet, and J.E. Karp Farnesyl transferase inhibitors in myeloid malignancies Blood Rev. 17 2003 123 129
50. T. Braun, and P. Fenaux Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia Br. J. Haematol. 141 2008 576 586
51. J. Cortes Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes J. Clin. Oncol. 23 2005 2805 2812
52. R. Kurzrock Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood 102 2003 4527 4534
53. V.P. Rao, and D.L. Epstein Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma BioDrugs 21 2007 167 177
54. Shepard, A.R. and Fleenor, D.L. (2009) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma, 20070232675. Google Patents.
55. C.E. Walters Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis J. Immunol. 168 2002 4087 4094
56. M. Crul Ras biochemistry and farnesyl transferase inhibitors: a literature survey Anticancer Drugs 12 2001 163 184
57. C.L. Strickland Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships J. Med. Chem. 42 1999 2125 2135
58. T.S. Reid Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes Biochemistry 43 2004 9000 9008
59. S. Duez Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: synthesis and biological evaluation of new farnesylpyrophosphate analogues Bioorg. Med. Chem. 18 2010 543 556
60. N.E. Kohl Protein farnesyltransferase inhibitors block the growth of Ras-dependent tumors in nude mice Proc. Natl. Acad. Sci. U. S. A. 91 1994 9141 9145
61. H-Y. Lee Development of tripeptidyl farnesyltransferase inhibitors Bioorg. Med. Chem. Lett. 12 2002 1599 1602
62. J.T. Hunt Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase J. Med. Chem. 39 1996 353 358
63. E. Van Cutsem Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J. Clin. Oncol. 22 2004 1430 1438
64. J-L. Harousseau A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Blood 114 2009 1166 1173
65. R.B. Lobell Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl: protein transferase type-1 Mol. Cancer Ther. 1 2002 747 758
66. S.L. Graham Pseudopeptide inhibitors of Ras farnesyl-protein transferase J. Med. Chem. 37 1994 725 732
67. Y. Qian Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics Bioorg. Med. Chem. 6 1998 293 299
68. A. Vasudevan Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I J. Med. Chem. 42 1999 1333 1340
69. J.Z. Sun Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine Cancer Res. 59 1999 4919 4926
70. H.E. Huber Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors J. Biol. Chem. 276 2001 24457 24465
71. H. Peng Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I Org. Biomol. Chem. 4 2006 1768 1784
72. Y.K. Peterson A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity J. Biol. Chem. 281 2006 12445 12450
73. M. Watanabe Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds J. Biol. Chem. 283 2008 9571 9579
74. D.B. Zimonjic In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells BMC Cancer 13 2013 198
75. L.N. Chan Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I PLoS ONE 6 2011 e26135
76. P. O'Dwyer Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors Ann. Oncol. 21 2010 42
77. E. Perola Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads J. Med. Chem. 43 2000 401 408
78. Y.K. Peterson Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation J. Med. Chem. 52 2009 4210 4220
79. K. Xu Models of ternary complexes for nonpeptidic farnesyltransferase inhibitors: insights into structure-based screen and design of potential anticancer therapeutics Mol. Model. Ann. 5 1999 203 217
80. A. Pedretti Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking J. Med. Chem. 45 2002 1460 1465
81. M-H. Ho Unraveling the catalytic pathway of metalloenzyme farnesyltransferase through QM/MM computation J. Chem. Theor. Comput. 5 2009 1657 1666